Prognostic Value of Preoperative N Subcategories in Patients with Stage IIIA N2 Non-Small Cell Lung Cancer

被引:1
作者
Oh, Na Eun [1 ,2 ]
Choe, Jooae [1 ,2 ]
Yun, Jae Kwang [3 ]
Ji, Wonjun [4 ]
Kim, Seonok [5 ]
Chae, Eun Jin [1 ,2 ]
Lee, Sang Min [1 ,2 ]
Seo, Joon Beom [1 ,2 ]
机构
[1] Univ Ulsan, Asan Med Ctr, Dept Radiol, Coll Med, 88 Olymp Ro 43 Gil, Seoul 138736, South Korea
[2] Univ Ulsan, Res Inst Radiol, Coll Med, Asan Med Ctr, 88 Olymp Ro 43 Gil, Seoul 138736, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Thorac & Cardiovasc Surg, 88 Olymp Ro 43 Gil, Seoul 138736, South Korea
[4] Univ Ulsan, Asan Med Ctr, Dept Internal Med, Div Pulmonol & Crit Care Med,Coll Med, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea
[5] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Clin Epidemiol & Biostat, 88 Olymp Ro 43 Gil, Seoul, South Korea
关键词
RISK-FACTORS; CHEMOTHERAPY; RESECTION; SURVIVAL; DISEASE; TRIAL;
D O I
10.1148/ryct.230347
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To evaluate the preoperative risk factors in patients with pathologic IIIA N2 non-small cell lung cancer (NSCLC) who underwent upfront surgery and to evaluate the prognostic value of new N subcategories. Materials and Methods: Patients with pathologic stage IIIA N2 NSCLC who underwent upfront surgery in a single tertiary center from January 2015 to April 2021 were retrospectively reviewed. Each patient's clinical N (cN) was assigned to one of six subcategories (cN0, cN1a, cN1b, cN2a1, cN2a2, and cN2b) based on recently proposed N descriptors. Cox regression analysis was used to identify the significant prognostic factors for recurrence-free survival (RFS) and overall survival (OS). Results: A total of 366 patients (mean age +/- SD, 62.0 years +/- 10.1; 202 male patients [55%]) were analyzed. The recurrence rate was 55% (203 of 366 patients) over a median follow-up of 37.3 months. Multivariable analysis demonstrated that cN (hazard ratios [HRs] for cN1 and cN2b compared with cN0, 1.66 [95% CI: 1.11, 2.48] and 2.11 [95% CI: 1.32, 3.38], respectively) and maximum lymph node (LN) size at N1 station (>= 12 mm; HR, 1.62 [95% CI: 1.15, 2.29]), in addition to clinical T category (HR, 1.51 [95% CI: 1.14, 1.99]), were independent prognostic factors for RFS. For OS, clinical N subcategories (cN1, cN2a2, and cN2b vs cN0; HRs, 1.91 [95% CI: 1.11, 3.27], 1.89 [95% CI: 1.13, 2.18], and 2.02 [95% CI: 1.07, 3.80], respectively) and LN size at N1 station (HR, 1.75 [95% CI: 1.12, 2.71]) were independent prognostic factors. For clinical N1, OS was further stratified according to LN size (log-rank test, P < .001). Conclusion: Assessing the proposed N subcategories by reporting single versus multistation involvement of N2 disease and maximum size of metastatic LN, reflecting metastatic burden, at preoperative CT may offer useful prognostic information for planning optimal treatment strategies.
引用
收藏
页数:10
相关论文
共 50 条
[21]   Postoperative radiotherapy in non-small cell lung cancer stage IIIA-N2: Focus and perspectives [J].
Wang, Pascal ;
Duchemann, Boris ;
Chouahnia, Kader ;
Matton, Lise ;
Benabadji, Ambre ;
Zelek, Laurent ;
Popotte, Hosni ;
Paix, Adrien .
BULLETIN DU CANCER, 2023, 110 (01) :101-112
[22]   Value of postoperative radiotherapy for stage IIIa-N2 non-small cell lung cancer: an analysis based on SEER database [J].
Yang, Ran ;
Gong, Jun ;
Liao, Zhengkai ;
Yu, Jing ;
Zhang, Junhong ;
Xie, Conghua .
TRANSLATIONAL CANCER RESEARCH, 2022, 11 (07) :2194-+
[23]   Surgery for stage IIIA-N2 non-small cell lung cancer: the jury is still out! [J].
Berzenji, Lawek ;
Beckers, Paul ;
Van Schil, Paul E. .
JOURNAL OF THORACIC DISEASE, 2019, 11 :S1153-S1156
[24]   Stage N2/IIIA Non Small Cell Lung Cancer: An Evidence-Based Review [J].
Komanapalli, Christopher B. ;
Thomas, Charles R., Jr. ;
Sukumar, Mithran S. .
CURRENT CANCER THERAPY REVIEWS, 2007, 3 (02) :127-139
[25]   N2-IIIA non-small cell lung cancer: a plea for surgery! [J].
Massard, Gilbert ;
Renaud, Stephane ;
Reeb, Jeremie ;
Santelmo, Nicola ;
Olland, Anne ;
Falcoz, Pierre-Emmanuel .
JOURNAL OF THORACIC DISEASE, 2016, 8 :S849-S854
[26]   Prognostic Value of Tumor Size in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer [J].
Chen, Chih-Yu ;
Wu, Bing-Ru ;
Chen, Chia-Hung ;
Cheng, Wen-Chien ;
Chen, Wei-Chun ;
Liao, Wei-Chih ;
Chen, Chih-Yi ;
Hsia, Te-Chun ;
Tu, Chih-Yen .
JOURNAL OF CLINICAL MEDICINE, 2020, 9 (05)
[27]   The Prognostic Role of Blood Inflammatory Biomarkers and EGFR Mutation Status in Stage IIIA/N2 Non-Small Cell Lung Cancer Patients Treated With Trimodality Therapy [J].
Yang, Hui ;
Wang, Kunlun ;
Li, Bingxu ;
Li, Shenglei ;
Li, Yan ;
Yuan, Ling .
FRONTIERS IN ONCOLOGY, 2021, 11
[28]   Improved Survival Associated with Neoadjuvant Chemoradiation in Patients with Clinical Stage IIIA(N2) Non-Small-Cell Lung Cancer [J].
Koshy, Matthew ;
Fedewa, Stacey A. ;
Malik, Renu ;
Ferguson, Mark K. ;
Vigneswaran, Wickii T. ;
Feldman, Lawrence ;
Howard, Andrew ;
Abdelhady, Khaled ;
Weichselbaum, Ralph R. ;
Virgo, Katherine S. .
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (07) :915-922
[29]   Paclitaxel, carboplatin and gemcitabine combination as induction chemotherapy for stage IIIA N2 bulky non-small cell lung cancer [J].
Giannitto, GC ;
Giuffrida, D ;
Pappalardo, A ;
Russo, A ;
Vincenzi, B ;
Saita, S ;
Potenza, E ;
Marletta, F ;
La Venia, G ;
Castorina, S ;
Bordonaro, R .
ONCOLOGY, 2005, 69 (04) :295-300
[30]   Effects of postoperative adjuvant radiotherapy on stage IIIA-N2 non-small cell lung cancer and prognostic analysis [J].
Wang, Tao ;
Jiang, Tao ;
Han, Yong ;
Zhu, Ailin ;
Xin, Shaowei ;
Xue, Menghua ;
Xin, Xiangbing ;
Lu, Qiang .
JOURNAL OF BUON, 2021, 26 (02) :328-335